US FDA declines to approve Immunitybio for bladder cancer treatment

Reuters · 05/11/2023 06:54
US FDA declines to approve Immunitybio for bladder cancer treatment

- Immunitybio Inc IBRX.O said on Thursday the U.S. Food and Drug Administration declined to approve its marketing application for a type of bladder cancer treatment.


(Reporting by Sriparna Roy in Bengaluru)

((Sriparna.Roy@thomsonreuters.com;))